Logo Image
|Articles|July 1, 2006

LCGC Supplements

  • Special Issues-07-01-2006
  • Volume 0
  • Issue 0

The Sands of Time Cannot be Stilled

The FDA has been implementing several changes in the way it does business, for example, relying on third-party inspections, academia, and industry in many new ways. The implementation of process analytical technology is among these changes.
External Link - article-416321.pdf

Articles in this issue

almost 20 years ago

Analytical Instrument Qualification

almost 20 years ago

GMP and Phase I Clinical Trials: Streamlining the Critical Path?

almost 20 years ago

Team Effort

almost 20 years ago

Rated PG: Pharmaceutical Guidance Suggested

almost 20 years ago

European Clinical Trial Regulations Undergo a Slow Revolution

almost 20 years ago

A Practical and Cost-Effective Risk Assessment for the Validation of Commercial Laboratory Computerized Systems

almost 20 years ago

Moving Biotech Products from CBER to CDER: A Work in Progress

almost 20 years ago

FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chief

almost 20 years ago

New Climate

almost 20 years ago

2006: A Regulatory Odyssey

Related Content